A core matrisome gene signature predicts cancer outcome

<p><b>Background:</b> Accumulating evidence implicates the tumour stroma as an important determinant of cancer progression but the protein constituents relevant for this effect are unknown. Here we utilised a bioinformatics approach to identify an extracellular matrix (ECM) gene s...

Full description

Bibliographic Details
Main Authors: Yuzhalin, A, Urbonas, T, Silva, M, Muschel, R, Gordon-Weeks, A
Format: Journal article
Language:English
Published: Cancer Research UK 2018
_version_ 1797086943459147776
author Yuzhalin, A
Urbonas, T
Silva, M
Muschel, R
Gordon-Weeks, A
author_facet Yuzhalin, A
Urbonas, T
Silva, M
Muschel, R
Gordon-Weeks, A
author_sort Yuzhalin, A
collection OXFORD
description <p><b>Background:</b> Accumulating evidence implicates the tumour stroma as an important determinant of cancer progression but the protein constituents relevant for this effect are unknown. Here we utilised a bioinformatics approach to identify an extracellular matrix (ECM) gene signature overexpressed in multiple cancer types and strongly predictive of adverse outcome. </p><p><b>Methods:</b> Gene expression levels in cancers were determined using Oncomine. Geneset enrichment analysis was performed using the Broad Institute desktop application. Survival analysis was performed using KM plotter. Survival data were generated from publically available genesets. </p><p><b>Results:</b> We analysed ECM genes significantly upregulated across a large cohort of patients with ovarian, lung, gastric and colon cancers and defined a signature of nine commonly upregulated genes. Each of these nine genes was considerably overexpressed in all the cancers studied, and cumulatively, their expression was associated with poor prognosis across all data sets. Further, the gene signature expression was associated with enrichment of genes governing processes linked to poor prognosis, such as EMT, angiogenesis, hypoxia, and inflammation. </p><p><b>Conclusions:</b> Here we identify a nine-gene ECM signature, which strongly predicts outcome across multiple cancer types and can be used for prognostication after validation in prospective cancer cohorts.</p>
first_indexed 2024-03-07T02:29:03Z
format Journal article
id oxford-uuid:a69d58d7-fd18-47f4-b592-5d4d82af1e04
institution University of Oxford
language English
last_indexed 2024-03-07T02:29:03Z
publishDate 2018
publisher Cancer Research UK
record_format dspace
spelling oxford-uuid:a69d58d7-fd18-47f4-b592-5d4d82af1e042022-03-27T02:48:30ZA core matrisome gene signature predicts cancer outcomeJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a69d58d7-fd18-47f4-b592-5d4d82af1e04EnglishSymplectic Elements at OxfordCancer Research UK2018Yuzhalin, AUrbonas, TSilva, MMuschel, RGordon-Weeks, A <p><b>Background:</b> Accumulating evidence implicates the tumour stroma as an important determinant of cancer progression but the protein constituents relevant for this effect are unknown. Here we utilised a bioinformatics approach to identify an extracellular matrix (ECM) gene signature overexpressed in multiple cancer types and strongly predictive of adverse outcome. </p><p><b>Methods:</b> Gene expression levels in cancers were determined using Oncomine. Geneset enrichment analysis was performed using the Broad Institute desktop application. Survival analysis was performed using KM plotter. Survival data were generated from publically available genesets. </p><p><b>Results:</b> We analysed ECM genes significantly upregulated across a large cohort of patients with ovarian, lung, gastric and colon cancers and defined a signature of nine commonly upregulated genes. Each of these nine genes was considerably overexpressed in all the cancers studied, and cumulatively, their expression was associated with poor prognosis across all data sets. Further, the gene signature expression was associated with enrichment of genes governing processes linked to poor prognosis, such as EMT, angiogenesis, hypoxia, and inflammation. </p><p><b>Conclusions:</b> Here we identify a nine-gene ECM signature, which strongly predicts outcome across multiple cancer types and can be used for prognostication after validation in prospective cancer cohorts.</p>
spellingShingle Yuzhalin, A
Urbonas, T
Silva, M
Muschel, R
Gordon-Weeks, A
A core matrisome gene signature predicts cancer outcome
title A core matrisome gene signature predicts cancer outcome
title_full A core matrisome gene signature predicts cancer outcome
title_fullStr A core matrisome gene signature predicts cancer outcome
title_full_unstemmed A core matrisome gene signature predicts cancer outcome
title_short A core matrisome gene signature predicts cancer outcome
title_sort core matrisome gene signature predicts cancer outcome
work_keys_str_mv AT yuzhalina acorematrisomegenesignaturepredictscanceroutcome
AT urbonast acorematrisomegenesignaturepredictscanceroutcome
AT silvam acorematrisomegenesignaturepredictscanceroutcome
AT muschelr acorematrisomegenesignaturepredictscanceroutcome
AT gordonweeksa acorematrisomegenesignaturepredictscanceroutcome
AT yuzhalina corematrisomegenesignaturepredictscanceroutcome
AT urbonast corematrisomegenesignaturepredictscanceroutcome
AT silvam corematrisomegenesignaturepredictscanceroutcome
AT muschelr corematrisomegenesignaturepredictscanceroutcome
AT gordonweeksa corematrisomegenesignaturepredictscanceroutcome